Codagenix employs a proprietary technology platform for the construction of live attenuated viral vaccines for multiple targets. Founded by Eckard Wimmer, J. Robert Coleman, and Steffen Mueller in 2011, Codagenix is backed by investors that include Topspin Partners, Euclidean Capital, and Adjuvant Capital and is headquartered in Stony Brook, New York.